Pharmacological management of symptoms in multiple sclerosis: Current approaches and future directions

The Lancet Neurology

Volumn 9, Issue 12, 2010, Pages 1182-1199

  Thompson, Alan J ^a   Toosy, Ahmed T ^a   Ciccarelli, Olga ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOPYRIDINE; ATROPINE; BACLOFEN; BOTULINUM TOXIN A; CANNABINOID; CANNABIS; CAPSAICIN; CARBAMAZEPINE; CLONAZEPAM; DANTROLENE; DESMOPRESSIN; DIAZEPAM; DOLASETRON MESILATE; DRONABINOL; ETIRACETAM; GABAPENTIN; GLUTETHIMIDE; INDORAMIN; ISONIAZID; ONDANSETRON; OXYBUTYNIN; PROPANTHELINE BROMIDE; PROPRANOLOL; RESINIFERATOXIN; SILDENAFIL; TIZANIDINE; TOLPERISONE; TOLTERODINE; TROSPIUM CHLORIDE; UNINDEXED DRUG;

ATAXIA; BLADDER DYSFUNCTION; BRAIN DEPTH STIMULATION; CLINICAL DECISION MAKING; CLINICAL TRIAL; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG TOLERABILITY; ERECTILE DYSFUNCTION; FATIGUE; GAMMA KNIFE RADIOSURGERY; GASTROINTESTINAL SYMPTOM; HALLUCINATION; HUMAN; LIVER FUNCTION; MULTIPLE SCLEROSIS; MUSCLE WEAKNESS; NEUROGENIC BLADDER; ORTHOSTATIC HYPOTENSION; OVERACTIVE BLADDER; PALLIATIVE THERAPY; PARESTHESIA; PHYSIOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; SYMPTOM; THALAMOTOMY; TREATMENT INDICATION; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; XEROSTOMIA;

DRUG THERAPY; HUMANS; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 78349289202     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70249-0     Document Type: Review

References (184)

1. Trisolini M, Honeycutt A, Wiener J, Lesesne S Global economic impact of multiple sclerosis. Multiple Sclerosis International Federation 2010 (accessed Aug 10, 2010). http://www.msif.org/en/resources/msif_resources/msif_publications/global_economic_impact_of_ms/index.html.
2. Goodman AD, Brown TR, Krupp LB, et al. Sustained-release oral fampridine in multiple sclerosis: a randomised, double-blind, controlled trial. Lancet 2009, 373:732-738.
3. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003, 362:1517-1526.
4. Shakespeare DT, Boggild M, Young C Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev 2003, 4. CD001332.
5. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. Neurology 1994, 44(11 suppl 9):70-78. United Kingdom Tizanidine Trial Group.
6. Nance PW, Sheremata WA, Lynch SG, et al. Relationship of the antispasticity effect of tizanidine to plasma concentration in patients with multiple sclerosis. Arch Neurol 1997, 54:731-736.
7. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. Neurology 1994, 44(11 suppl 9):34-42. for the US Tizanidine Study Group.
8. Mueller ME, Gruenthal M, Olson WL, Olson WH Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil 1997, 78:521-524.
9. Cutter NC, Scott DD, Johnson JC, Whiteneck G Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil 2000, 81:164-169.
10. Zajicek JP, Sanders HP, Wright DE, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry 2005, 76:1664-1669.
11. Wade DT, Makela P, Robson P, House H, Bateman C Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler 2004, 10:434-441.
12. Eyssette M, Rohmer F, Serratrice G, Warter JM, Boisson D Multi-centre, double-blind trial of a novel antispastic agent, tizanidine, in spasticity associated with multiple sclerosis. Curr Med Res Opin 1988, 10:699-708.
13. Groves L, Shellenberger MK, Davis CS Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther 1998, 15:241-251.
14. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 2007, 6:1094-1105.
15. Beard S, Hunn A, Wight J Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess 2003, 7:1-111. iii, ix-x.
16. Smith CR, LaRocca NG, Giesser BS, Scheinberg LC High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991, 41:1829-1831.
17. Stamenova P, Koytchev R, Kuhn K, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol 2005, 12:453-461.
18. Baker D, Pryce G, Croxford JL, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature 2000, 404:84-87.
19. Hobart JC, Riazi A, Thompson AJ, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain 2006, 129:224-234.
20. Wade DT, Collin C, Stott C, Duncombe P Meta-analysis of the efficacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler 2010, 16:707-714.
21. Zahavi A, Geertzen JH, Middel B, Staal M, Rietman JS Long term effect (more than five years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry 2004, 75:1553-1557.
22. Boviatsis EJ, Kouyialis AT, Korfias S, Sakas DE Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg 2005, 107:289-295.
23. Bensmail D, Salva MA Quera, Roche N, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology 2006, 67:1432-1436.
24. Cooper JA, Ridley B Response of intrathecal baclofen resistance to dose reduction. Neurology 2006, 67:1495-1496.
25. Schuele SU, Kellinghaus C, Shook SJ, Boulis N, Bethoux FA, Loddenkemper T Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology 2005, 64:1086-1087.
26. Dalton CM, Keenan E, Jarrett L, Buckley L, Stevenson VL The safety of baclofen in pregnancy: intrathecal therapy in multiple sclerosis. Mult Scler 2008, 14:571-572.
27. Sadiq SA, Poopatana CA Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol 2007, 254:1464-1465.
28. Jarrett L, Nandi P, Thompson AJ Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role?. J Neurol Neurosurg Psychiatry 2002, 73:705-709.
29. Hyman N, Barnes M, Bhakta B, et al. Botulinum toxin (Dysport) treatment of hip adductor spasticity in multiple sclerosis: a prospective, randomised, double blind, placebo controlled, dose ranging study. J Neurol Neurosurg Psychiatry 2000, 68:707-712.
30. Dolly JO, Aoki KR The structure and mode of action of different botulinum toxins. Eur J Neurol 2006, 13(suppl 4):1-9.
31. Giovannelli M, Borriello G, Castri P, Prosperini L, Pozzilli C Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis. Clin Rehabil 2007, 21:331-337.
32. Mills RJ, Yap L, Young CA Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev 2007, 1. CD005029.
33. Hallett M, Lindsey JW, Adelstein BD, Riley PO Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology 1985, 35:1374-1377.
34. Duquette P, Pleines J, du Souich P Isoniazid for tremor in multiple sclerosis: a controlled trial. Neurology 1985, 35:1772-1775.
35. Koller WC Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol 1984, 41:280-281.
36. Rice GP, Lesaux J, Vandervoort P, Macewan L, Ebers GC Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry 1997, 62:282-284.
37. Gbadamosi J, Buhmann C, Moench A, Heesen C Failure of ondansetron in treating cerebellar tremor in MS patients-an open-label pilot study. Acta Neurol Scand 2001, 104:308-311.
38. Monaca-Charley C, Stojkovic T, Duhamel A, De Seze J, Ferriby D, Vermersch P Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol 2003, 250:1190-1194.
39. Fox P, Bain PG, Glickman S, Carroll C, Zajicek J The effect of cannabis on tremor in patients with multiple sclerosis. Neurology 2004, 62:1105-1109.
40. Feys P, D'hooghe MB, Nagels G, Helsen WF The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler 2009, 15:371-378.
41. Sechi GP, Zuddas M, Piredda M, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology 1989, 39:1113-1115.
42. Aisen ML, Holzer M, Rosen M, Dietz M, McDowell F Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury. Arch Neurol 1991, 48:513-515.
43. Bittar RG, Hyam J, Nandi D, et al. Thalamotomy versus thalamic stimulation for multiple sclerosis tremor. J Clin Neurosci 2005, 12:638-642.
44. Schuurman PR, Bosch DA, Bossuyt PM, et al. A comparison of continuous thalamic stimulation and thalamotomy for suppression of severe tremor. N Engl J Med 2000, 342:461-468.
45. Schuurman PR, Bosch DA, Merkus MP, Speelman JD Long-term follow-up of thalamic stimulation versus thalamotomy for tremor suppression. Mov Disord 2008, 23:1146-1153.
46. Niranjan A, Kondziolka D, Baser S, Heyman R, Lunsford LD Functional outcomes after gamma knife thalamotomy for essential tremor and MS-related tremor. Neurology 2000, 55:443-446.
47. Mathieu D, Kondziolka D, Niranjan A, Flickinger J, Lunsford LD Gamma knife thalamotomy for multiple sclerosis tremor. Surg Neurol 2007, 68:394-399.
48. Solari A, Uitdehaag B, Giuliani G, Pucci E, Taus C Aminopyridines for symptomatic treatment in multiple sclerosis. Cochrane Database Syst Rev 2003, 2. CD001330.
49. Goodman AD, Cohen JA, Cross A, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo-controlled, dose-ranging study. Mult Scler 2007, 13:357-368.
50. Goodman AD, Brown TR, Cohen JA, et al. Dose comparison trial of sustained-release fampridine in multiple sclerosis. Neurology 2008, 71:1134-1141.
51. Hobart JC, Riazi A, Lamping DL, Fitzpatrick R, Thompson AJ Measuring the impact of MS on walking ability: the 12-Item MS Walking Scale (MSWS-12). Neurology 2003, 60:31-36.
52. Thompson A, Polman C Improving function: a new treatment era for multiple sclerosis?. Lancet 2009, 373:697-698.
53. DasGupta R, Fowler CJ Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs 2003, 63:153-166.
54. Fowler CJ, Griffiths D, de Groat WC The neural control of micturition. Nat Rev Neurosci 2008, 9:453-466.
55. Fowler CJ, Panicker JN, Drake M, et al. A UK consensus on the management of the bladder in multiple sclerosis. Postgrad Med J 2009, 85:552-559.
56. Hashim H, Abrams P How should patients with an overactive bladder manipulate their fluid intake?. BJU Int 2008, 102:62-66.
57. McClurg D, Ashe RG, Lowe-Strong AS Neuromuscular electrical stimulation and the treatment of lower urinary tract dysfunction in multiple sclerosis-a double blind, placebo controlled, randomised clinical trial. Neurourol Urodyn 2008, 27:231-237.
58. Guay DR Cranberry and urinary tract infections. Drugs 2009, 69:775-807.
59. Hess MJ, Hess PE, Sullivan MR, Nee M, Yalla SV Evaluation of cranberry tablets for the prevention of urinary tract infections in spinal cord injured patients with neurogenic bladder. Spinal Cord 2008, 46:622-626.
60. O'Riordan JI, Doherty C, Javed M, Brophy D, Hutchinson M, Quinlan D Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis?. J Urol 1995, 153:1114-1116.
61. Dasgupta P, Haslam C, Goodwin R, Fowler CJ The 'Queen Square bladder stimulator': a device for assisting emptying of the neurogenic bladder. Br J Urol 1997, 80:234-237.
62. Prasad RS, Smith SJ, Wright H Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil 2003, 17:42-47.
63. Nicholas RS, Friede T, Hollis S, Young CA Anticholinergics for urinary symptoms in multiple sclerosis. Cochrane Database Syst Rev 2009, 1. CD004193.
64. Gajewski JB, Awad SA Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986, 135:966-968.
65. Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol 2007, 177:208-213.
66. Amend B, Hennenlotter J, Schafer T, Horstmann M, Stenzl A, Sievert KD Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008, 53:1021-1028.
67. Duthie J, Wilson DI, Herbison GP, Wilson D Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2007, 3. CD005493.
68. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007, 41:335-340.
69. Kalsi V, Gonzales G, Popat R, et al. Botulinum injections for the treatment of bladder symptoms of multiple sclerosis. Ann Neurol 2007, 62:452-457.
70. Bosma R, Wynia K, Havlikova E, De Keyser J, Middel B Efficacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand 2005, 112:1-5.
71. Freeman RM, Adekanmi O, Waterfield MR, Waterfield AE, Wright D, Zajicek J The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct 2006, 17:636-641.
72. MacDonald R, Monga M, Fink HA, Wilt TJ Neurotoxin treatments for urinary incontinence in subjects with spinal cord injury or multiple sclerosis: a systematic review of effectiveness and adverse effects. J Spinal Cord Med 2008, 31:157-165.
73. Fjorback MV, Rijkhoff N, Petersen T, Nohr M, Sinkjaer T Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn 2006, 25:349-355.
74. Kabay S, Kabay SC, Yucel M, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn 2009, 28:964-968.
75. Wallace PA, Lane FL, Noblett KL Sacral nerve neuromodulation in patients with underlying neurologic disease. Am J Obstet Gynecol 2007, 197:96-195.
76. Fowler CJ, Miller JR, Sharief MK, Hussain IF, Stecher VJ, Sweeney M A double blind, randomised study of sildenafil citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry 2005, 76:700-705.
77. Safarinejad MR Evaluation of the safety and efficacy of sildenafil citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol 2009, 181:252-258.
78. DasGupta R, Wiseman OJ, Kanabar G, Fowler CJ, Mikol DD Efficacy of sildenafil in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol 2004, 171:1189-1193.
79. Cardozo L, Hessdorfer E, Milani R, et al. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 2008, 102:1120-1127.
80. Chapple C, Steers W, Norton P, et al. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005, 95:993-1001.
81. Cvetkovic RS, Plosker GL Desmopressin: in adults with nocturia. Drugs 2005, 65:99-107.
82. Kavia R, De RD, Constantinescu C, Stott C, Fowler C Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler 2010, 16:1349-1359.
83. Chia YW, Fowler CJ, Kamm MA, Henry MM, Lemieux MC, Swash M Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol 1995, 242:105-108.
84. Preziosi G, Emmanuel A Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol 2009, 3:417-423.
85. Cameron KJ, Nyulasi IB, Collier GR, Brown DJ Assessment of the effect of increased dietary fibre intake on bowel function in patients with spinal cord injury. Spinal Cord 1996, 34:277-283.
86. Wiesel PH, Norton C, Glickman S, Kamm MA Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol 2001, 13:441-448.
87. House JG, Stiens SA Pharmacologically initiated defecation for persons with spinal cord injury: effectiveness of three agents. Arch Phys Med Rehabil 1997, 78:1062-1065.
88. Wiesel PH, Norton C, Roy AJ, Storrie JB, Bowers J, Kamm MA Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000, 69:240-243.
89. Chiotakakou-Faliakou E, Kamm MA, Roy AJ, Storrie JB, Turner IC Biofeedback provides long-term benefit for patients with intractable, slow and normal transit constipation. Gut 1998, 42:517-521.
90. Faaborg PM, Christensen P, Kvitsau B, Buntzen S, Laurberg S, Krogh K Long-term outcome and safety of transanal colonic irrigation for neurogenic bowel dysfunction. Spinal Cord 2009, 47:545-549.
91. Tan EK, Vaizey C, Cornish J, Darzi A, Tekkis PP Surgical strategies for faecal incontinence-a decision analysis between dynamic graciloplasty, artificial bowel sphincter and end stoma. Colorectal Dis 2008, 10:577-586.
92. Jarrett ME, Dudding TC, Nicholls RJ, Vaizey CJ, Cohen CR, Kamm MA Sacral nerve stimulation for fecal incontinence related to obstetric anal sphincter damage. Dis Colon Rectum 2008, 51:531-537.
93. Tepavcevic DK, Kostic J, Basuroski ID, Stojsavljevic N, Pekmezovic T, Drulovic J The impact of sexual dysfunction on the quality of life measured by MSQoL-54 in patients with multiple sclerosis. Mult Scler 2008, 14:1131-1136.
94. Lombardi G, Macchiarella A, Del Popolo G Efficacy and safety of tadalafil for erectile dysfunction in patients with multiple sclerosis. J Sex Med 2010, 7:2192-2200.
95. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med 1997, 336:1-7. for Medicated Urethral System for Erection (MUSE) Study Group.
96. Brown DA, Kyle JA, Ferrill MJ Assessing the clinical efficacy of sildenafil for the treatment of female sexual dysfunction. Ann Pharmacother 2009, 43:1275-1285.
97. Hadjimichael O, Vollmer T, Oleen-Burkey M Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes 2008, 6:100.
98. Stroud NM, Minahan CL The impact of regular physical activity on fatigue, depression and quality of life in persons with multiple sclerosis. Health Qual Life Outcomes 2009, 7:68.
99. Schwid SR, Petrie MD, Murray R, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology 2003, 60:1955-1960.
100. Mainero C, Inghilleri M, Pantano P, et al. Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine. Neurology 2004, 62:2044-2050.
101. A randomized controlled trial of amantadine in fatigue associated with multiple sclerosis. Can J Neurol Sci 1987, 14:273-278. The Canadian MS Research Group.
102. Cohen RA, Fisher M Amantadine treatment of fatigue associated with multiple sclerosis. Arch Neurol 1989, 46:676-680.
103. Krupp LB, Coyle PK, Doscher C, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology 1995, 45:1956-1961.
104. Zifko UA, Rupp M, Schwarz S, Zipko HT, Maida EM Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 2002, 249:983-987.
105. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 2002, 72:179-183.
106. Stankoff B, Waubant E, Confavreux C, et al. Modafinil for fatigue in MS: a randomized placebo-controlled double-blind study. Neurology 2005, 64:1139-1143.
107. Lange R, Volkmer M, Heesen C, Liepert J Modafinil effects in multiple sclerosis patients with fatigue. J Neurol 2009, 256:645-650.
108. Weinshenker BG, Penman M, Bass B, Ebers GC, Rice GP A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology 1992, 42:1468-1471.
109. Sheean GL, Murray NM, Rothwell JC, Miller DH, Thompson AJ An open-labelled clinical and electrophysiological study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain 1998, 121:967-975.
110. Rossini PM, Pasqualetti P, Pozzilli C, et al. Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler 2001, 7:354-358.
111. Lebrun C, Alchaar H, Candito M, Bourg V, Chatel M Levocarnitine administration in multiple sclerosis patients with immunosuppressive therapy-induced fatigue. Mult Scler 2006, 12:321-324.
112. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci 2004, 218:103-108.
113. Metz LM, Patten SB, Archibald CJ, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry 2004, 75:1045-1047.
114. Putzki N, Yaldizli O, Tettenborn B, Diener HC Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci 2009, 285:109-113.
115. Chiaravalloti ND, DeLuca J Cognitive impairment in multiple sclerosis. Lancet Neurol 2008, 7:1139-1151.
116. Potagas C, Giogkaraki E, Koutsis G, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci 2008, 267:100-106.
117. O'Brien AR, Chiaravalloti N, Goverover Y, DeLuca J Evidenced-based cognitive rehabilitation for persons with multiple sclerosis: a review of the literature. Arch Phys Med Rehabil 2008, 89:761-769.
118. Fischer JS, Priore RL, Jacobs LD, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol 2000, 48:885-892.
119. Patti F, Amato MP, Bastianello S, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler 2010, 16:68-77.
120. Krupp LB, Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE Donepezil improved memory in multiple sclerosis in a randomized clinical trial. Neurology 2004, 63:1579-1585.
121. Christodoulou C, Melville P, Scherl WF, MacAllister WS, Elkins LE, Krupp LB Effects of donepezil on memory and cognition in multiple sclerosis. J Neurol Sci 2006, 245:127-136.
122. Shaygannejad V, Janghorbani M, Ashtari F, Zanjani HA, Zakizade N Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci 2008, 35:476-481.
123. Villoslada P, Arrondo G, Sepulcre J, Alegre M, Artieda J Memantine induces reversible neurologic impairment in patients with MS. Neurology 2009, 72:1630-1633.
124. Lovera JF, Frohman E, Brown TR, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler 2010, 16:715-723.
125. Geisler MW, Sliwinski M, Coyle PK, Masur DM, Doscher C, Krupp LB The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol 1996, 53:185-188.
126. Lovera J, Bagert B, Smoot K, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler 2007, 13:376-385.
127. Morrow SA, Kaushik T, Zarevics P, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol 2009, 256:1095-1102.
128. Pliskin NH, Hamer DP, Goldstein DS, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology 1996, 47:1463-1468.
129. Flechter S, Vardi J, Finkelstein Y, Pollak L Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J 2007, 9:457-459.
130. NCT00062972 Improving memory in patients with multiple sclerosis, (accessed Oct 27, 2010). http://clinicaltrials.gov/ct2/show/NCT00062972.
131. Patten SB, Beck CA, Williams JV, Barbui C, Metz LM Major depression in multiple sclerosis: a population-based perspective. Neurology 2003, 61:1524-1527.
132. Schiffer RB, Wineman NM, Weitkamp LR Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry 1986, 143:94-95.
133. Patten SB, Svenson LW, Metz LM Psychotic disorders in MS: population-based evidence of an association. Neurology 2005, 65:1123-1125.
134. Feinstein A Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci 2006, 245:63-66.
135. Thomas PW, Thomas S, Hillier C, Galvin K, Baker R Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev 2006, 1. CD004431.
136. Flax JW, Gray J, Herbert J Effect of fluoxetine on patients with multiple sclerosis. Am J Psychiatry 1991, 148:1603.
137. Scott TF, Nussbaum P, McConnell H, Brill P Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurol Res 1995, 17:421-422.
138. Barak Y, Ur E, Achiron A Moclobemide treatment in multiple sclerosis patients with comorbid depression: an open-label safety trial. J Neuropsychiatry Clin Neurosci 1999, 11:271-273.
139. Panitch HS, Thisted RA, Smith RA, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol 2006, 59:780-787.
140. Pioro EP, Brooks BR, Cummings J, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol 2010, 68:693-702.
141. Schiffer RB, Herndon RM, Rudick RA Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med 1985, 312:1480-1482.
142. Brochet B, Deloire MS, Ouallet JC, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain 2009, 25:211-217.
143. Clifford DB, Trotter JL Pain in multiple sclerosis. Arch Neurol 1984, 41:1270-1272.
144. Hirsh AT, Turner AP, Ehde DM, Haselkorn JK Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil 2009, 90:646-651.
145. Vacca G, Marano E, Morra V Brescia, et al. Multiple sclerosis and headache co-morbidity. A case-control study. Neurol Sci 2007, 28:133-135.
146. Hooge JP, Redekop WK Trigeminal neuralgia in multiple sclerosis. Neurology 1995, 45:1294-1296.
147. Lunardi G, Leandri M, Albano C, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology 1997, 48:1714-1717.
148. Solaro C, Messmer UM, Uccelli A, Leandri M, Mancardi GL Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol 2000, 44:45-48.
149. Zvartau-Hind M, Din MU, Gilani A, Lisak RP, Khan OA Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000, 55:1587-1588.
150. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol 2003, 250:542-545. DMKG Study Group.
151. Broggi G, Ferroli P, Franzini A, et al. Operative findings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery 2004, 55:830-838.
152. Zorro O, Lobato-Polo J, Kano H, Flickinger JC, Lunsford LD, Kondziolka D Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology 2009, 73:1149-1154.
153. Houtchens MK, Richert JR, Sami A, Rose JW Open label gabapentin treatment for pain in multiple sclerosis. Mult Scler 1997, 3:250-253.
154. Cianchetti C, Zuddas A, Randazzo AP, Perra L, Marrosu MG Lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations. Neurology 1999, 53:433.
155. Breuer B, Pappagallo M, Knotkova H, Guleyupoglu N, Wallenstein S, Portenoy RK A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther 2007, 29:2022-2030.
156. Rossi S, Mataluni G, Codeca C, et al. Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study. Eur J Neurol 2009, 16:360-366.
157. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin 2007, 23:17-24.
158. Svendsen KB, Jensen TS, Bach FW Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ 2004, 329:253.
159. Rog DJ, Nurmikko TJ, Friede T, Young CA Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology 2005, 65:812-819.
160. Rog DJ, Nurmikko TJ, Young CA Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial. Clin Ther 2007, 29:2068-2079.
161. Wissel J, Haydn T, Muller J, et al. Low dose treatment with the synthetic cannabinoid Nabilone significantly reduces spasticity-related pain: a double-blind placebo-controlled cross-over trial. J Neurol 2006, 253:1337-1341.
162. Warke K, Al-Smadi J, Baxter D, Walsh DM, Lowe-Strong AS Efficacy of transcutaneous electrical nerve stimulation (TENS) for chronic low-back pain in a multiple sclerosis population: a randomized, placebo-controlled clinical trial. Clin J Pain 2006, 22:812-819.
163. Chitsaz A, Janghorbani M, Shaygannejad V, Ashtari F, Heshmatipour M, Freeman J Sensory complaints of the upper extremities in multiple sclerosis: relative efficacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain 2009, 25:281-285.
164. Kumar K, Hunter G, Demeria D Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience. Neurosurgery 2006, 58:481-496.
165. Solaro C, Brichetto G, Amato MP, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology 2004, 63:919-921.
166. van Kleef M, van Genderen WE, Narouze S, et al. 1. Trigeminal neuralgia. Pain Pract 2009, 9:252-259.
167. Solaro C, Uccelli MM, Guglieri P, Uccelli A, Mancardi GL Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler 2000, 6:192-193.
168. Solaro C, Tanganelli P Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry 2004, 75:341.
169. Morgan JC, Hess DC, Sethi KD Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology 2004, 62:2143.
170. Sakurai M, Kanazawa I Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci 1999, 162:162-168.
171. Freynhagen R, Bennett MI Diagnosis and management of neuropathic pain. BMJ 2009, 339:b3002.
172. Tan T, Barry P, Reken S, Baker M Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ 2010, 340:c1079.
173. Cruccu G, Aziz TZ, Garcia-Larrea L, et al. EFNS guidelines on neurostimulation therapy for neuropathic pain. Eur J Neurol 2007, 14:952-970.
174. Straube A, Leigh RJ, Bronstein A, et al. EFNS task force-therapy of nystagmus and oscillopsia. Eur J Neurol 2004, 11:83-89.
175. Averbuch-Heller L, Zivotofsky AZ, Das VE, DiScenna AO, Leigh RJ Investigations of the pathogenesis of acquired pendular nystagmus. Brain 1995, 118:369-378.
176. Starck M, Albrecht H, Pollmann W, Dieterich M, Straube A Acquired pendular nystagmus in multiple sclerosis: an examiner-blind cross-over treatment study of memantine and gabapentin. J Neurol 2010, 257:322-327.
177. Thurtell MJ, Joshi AC, Leone AC, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol 2010, 67:676-680.
178. Abraham SS, Yun PT Laryngopharyngeal dysmotility in multiple sclerosis. Dysphagia 2002, 17:69-74.
179. Fry DK, Pfalzer LA, Chokshi AR, Wagner MT, Jackson ES Randomized control trial of effects of a 10-week inspiratory muscle training program on measures of pulmonary function in persons with multiple sclerosis. J Neurol Phys Ther 2007, 31:162-172.
180. Chiara T, Martin AD, Davenport PW, Bolser DC Expiratory muscle strength training in persons with multiple sclerosis having mild to moderate disability: effect on maximal expiratory pressure, pulmonary function, and maximal voluntary cough. Arch Phys Med Rehabil 2006, 87:468-473.
181. Altintas A, Demir T, Ikitimur HD, Yildirim N Pulmonary function in multiple sclerosis without any respiratory complaints. Clin Neurol Neurosurg 2007, 109:242-246.
182. Frohman EM, Zhang H, Dewey RB, Hawker KS, Racke MK, Frohman TC Vertigo in MS: utility of positional and particle repositioning maneuvers. Neurology 2000, 55:1566-1569.
183. Blanco Y, Compta Y, Graus F, Saiz A Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Mult Scler 2008, 14:694-697.
184. Marcel C, Anheim M, Flamand-Rouviere C, et al. Symptomatic paroxysmal dysarthria-ataxia in demyelinating diseases. J Neurol 2010, 257:1369-1372.